Clinical Trials

  1. RICHARD RIEGELMAN, M.D., PH.D.
  1. The George Washington University Medical Center;
    Washington, D.C. 20037

    Excerpt

    To the editor: The limitations of randomized trials for assessing the efficacy of prophylactic therapy and efficacy in clinical practice have recently been addressed by Feinstein (1). Controlled clinical trials are even more limited in their ability to assess safety.

    In assessing safety randomized trials are inherently limited by their size, duration, and failure to reflect the realities of clinical practice. For instance, a large randomized trial with 500 patients in each group has a 39% probability of seeing a side effect that occurs once in 1000 uses such as eye damage from practolol; a 5% probability of seeing a

    This 100-word excerpt has been provided in the absence of an abstract.

    « Previous | Next Article »Table of Contents